CARA vs. IMRX, BOLT, LEXX, RMTI, UNCY, XLO, APLM, PMN, NBRV, and MRKR
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Immuneering (IMRX), Bolt Biotherapeutics (BOLT), Lexaria Bioscience (LEXX), Rockwell Medical (RMTI), Unicycive Therapeutics (UNCY), Xilio Therapeutics (XLO), Apollomics (APLM), ProMIS Neurosciences (PMN), Nabriva Therapeutics (NBRV), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical preparations" industry.
Immuneering (NASDAQ:IMRX) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.
Immuneering has a net margin of 0.00% compared to Immuneering's net margin of -565.21%. Cara Therapeutics' return on equity of -52.49% beat Immuneering's return on equity.
In the previous week, Cara Therapeutics had 3 more articles in the media than Immuneering. MarketBeat recorded 5 mentions for Cara Therapeutics and 2 mentions for Immuneering. Cara Therapeutics' average media sentiment score of 0.19 beat Immuneering's score of 0.15 indicating that Immuneering is being referred to more favorably in the media.
Immuneering presently has a consensus target price of $13.50, suggesting a potential upside of 794.04%. Cara Therapeutics has a consensus target price of $9.75, suggesting a potential upside of 1,191.39%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Cara Therapeutics is more favorable than Immuneering.
Cara Therapeutics received 641 more outperform votes than Immuneering when rated by MarketBeat users. Likewise, 74.94% of users gave Cara Therapeutics an outperform vote while only 60.53% of users gave Immuneering an outperform vote.
Immuneering has higher earnings, but lower revenue than Cara Therapeutics. Immuneering is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
67.7% of Immuneering shares are held by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are held by institutional investors. 23.0% of Immuneering shares are held by company insiders. Comparatively, 4.2% of Cara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Immuneering has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.
Summary
Immuneering beats Cara Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
